Astrivax Therapeutics is a clinical-stage biopharmaceutical company on a mission to end virus-driven cancer, the second leading preventable cause of cancer after smoking
Astrivax Therapeutics is a clinical-stage biopharmaceutical company on a mission to end virus-driven cancer, the second leading preventable cause of cancer after smoking. Its clinically validated Launch-iT platform generates durable, antigen-specific T-cell responses that clear virus-infected cells, supported by a scalable, tech-transfer–ready manufacturing process.